Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accutane Risk Management Program Changes Held Up By Celgene Patents

This article was originally published in The Pink Sheet Daily

Executive Summary

Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.

You may also be interested in...



FDA Approves "Unprecedented" Risk Management Program For Accutane

Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.

FDA Approves "Unprecedented" Risk Management Program For Accutane

Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.

Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS059957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel